Geoffrey Spolyar

Cooley advised ERYTECH Pharma on its $143.7 million global offering of an aggregate of 6,180,137 ordinary shares, including the full exercise of the underwriters’ option to purchase additional shares. The global offering consisted of a US IPO of 5,389,021 American Depositary Shares, each representing one ordinary share and a concurrent private placement in Europe and other countries outside of the US and Canada of 791,116 ordinary shares.

Cooley is advising ZELTIQ Aesthetics (NASDAQ: ZLTQ) on its approximately $2.5 billion all cash sale to Allergan (NYSE: AGN), a leading global biopharmaceutical company.

Cooley recently advised on the initial public offerings for UK life sciences companies Nightstar Therapeutics and NuCana. These transactions are the latest example of Cooley’s commitment and leadership in the life sciences sector.

Jazz Pharmaceuticals in its acquisition of Redx Pharma's (Redx) pan-RAF inhibitor program for the potential treatment of RAF and RAS mutant tumors. Redx will perform certain pre-clinical activities for the program under a separate collaboration agreement with Jazz. Jazz will be responsible for further development, regulatory activities and commercialization. Jazz will pay Redx an upfront payment of $3.5 million. Redx is eligible to receive up to $203 million in development, regulatory and commercial milestone payments and incremental tiered royalties in mid-single digit percentage, based on any future net sales.

Cooley advised X4 Pharmaceuticals in its exclusive license agreement with Abbisko Therapeutics granting Abbisko exclusive rights to develop and commercialize maxorixafor in combination with checkpoint inhibitors or other agents in oncology indications in China, Taiwan, Hong Kong and Macau.